Generic Name and Formulations:
Guaifenesin 400mg; pseudoephedrine HCl 60mg; per caplet.
Ascher, B.F & Company
Indications for CONGESTAC:
Nasal, sinus and chest congestion.
1 caplet every 4–6 hours; max 4 caplets/24 hours.
<6yrs: not recommended. 6–12yrs: ½ caplet every 4–6 hours; max 2 caplets/24 hours.
During or within 14 days of MAOIs.
Cardiovascular disease. Hypertension. Thyroid disease. Diabetes. GI or GU obstruction. Asthma. Lower respiratory disorders.
Expectorant + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. β-blockers increase pressor effects of sympathomimetics. Antagonizes antihypertensives.
Nervousness, dizziness, insomnia.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC